Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | WZTL-002 |
| Trade Name | |
| Synonyms | WZTL 002WZTL002|Autologous 1928T2z CAR T-cells |
| Drug Descriptions |
WZTL-002 is composed of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing CD28 and TLR2 co-stimulatory domains, which decrease tumor growth (Blood (2023) 142 (Supplement 1): 890). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | C170905 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| WZTL-002 | WZTL-002 | 0 | 1 |